Pipeline

Aptadel’s technology is based in a delivery platform for different therapeutic agents. Our Aptamers technology allows us to conjugate numerous therapeutic agents directed against tumour cells with improved safety and specificity.

Aptadel's pipeline status

Aptadel’s main program is dedicated to fight childhood cancer, in particular Ewing Sarcoma (ES). ES is a rare type of cancerous tumour that grows in bones or soft tissue. It mainly affects children and young people, but is also seen in adults. These tumors are very aggressive, they tend to reappear and develop metastasis after chemotherapy. ES is the second most diagnosed form of primary bone cancer in children and young adults. Due to the lack of effective treatments, the survival of patients with pediatric sarcoma that present metastasis at the time of diagnosis is barely 20%.

Aptadel is also currently developing other programs directed to adult cancer types. Our aptamer platform allows us to target a wide variety of cancer types.

Program
DISCOVERY
LEAD OPTIMIZATION
IND enabling studies
Phase I/IIa
ADEL-101
(Ewing Sarcoma)
ADEL-102
(New indication)
ADEL-103
(New indication)
ADEL-101 (Ewing Sarcoma) - Preclinic
LEAD OPTIMIZATION
ADEL-102 (New indication) - Preclinic
DISCOVERY
ADEL-103 (New indication) - Preclinic
DISCOVERY
ADEL-101 (Ewing Sarcoma)
Lead Optimization
ADEL-102 (New indication)
Discovery
ADEL-103 (New indication)
Discovery